Deregulation of Toll-like receptor (TLR) mediated responses can have devastating effects on the host if left unchecked. It is, therefore, critical that control is exerted at several levels. In this review, we discuss post-translational modification of TLRs and their associated signaling molecules as one such means of control. In particular, we focus on the phosphorylation, ubiquitination and de-ubiquitination of various components of TLR signaling pathways.
INTRODUCTION
Toll-like receptors (TLRs) play a critical role in the innate immune response against invading pathogens. Characterised by an extracellular leucine-rich repeat region and a conserved cytoplasmic Toll/interleukin-1 (TIR) domain, TLRs recognise a plethora of bacterial and viral products referred to as pathogen-associated molecular patterns (PAMPs). Several of these PAMPs have been described; for example, bacterial lipopeptides and lipopolysaccharide are recognised by TLR2 and TLR4, respectively, double-stranded RNA is recognised by TLR3, flagellin by TLR5 and unmethylated CpG DNA by TLR9. 1 Details of the signaling pathways emanating from the various receptors are still emerging. In general, ligand binding induces the formation of a receptor complex containing adaptor molecules that act as bridges to couple the activated receptors to downstream kinase cascades. This leads to the eventual activation of specific transcription factors and the induction of proinflammatory cytokines or anti-viral genes that function to clear the invading pathogen. Differences in adaptor usage have been described, for example, TLR4 recruits the adaptors Mal and MyD88 to activate NF-κB while recruitment of the adaptors Toll/IL-1R domain-containing adaptor inducing interferon-beta (TRIF) and TRIFrelated adaptor molecule (TRAM) leads to the activation of interferon regulatory factor 3 (IRF-3). TLR3 recruits TRIF exclusively leading also to the activation of IRF3 and the induction of type I interferons (IFNs). Most other TLRs have been reported to bind MyD88 which appears to be a universal adaptor in these signalling pathways.
Tight regulation of the immune response is crucial for maintaining homeostasis and preventing the excessive induction of pro-inflammatory mediators which can be detrimental to the host. Control is exerted at several levels. In this review, we will discuss the post-translational modification of TLR signaling molecules which is emerging as a key factor in co-ordinating the positive and negative regulation of TLR-mediated responses.
PHOSPHORYLATION

Phosphorylation of Toll-like receptors
Activation of TLR signaling pathways typically involves the assembly of multiprotein complexes at the cell membrane. There are several lines of evidence to suggest that protein phosphorylation is required for the formation of these complexes and possibly the recruitment of downstream signaling components. For example, phosphorylation of TLR2 on specific tyrosine residues is required for NF-κB activation following exposure to heat-killed Staphylococcus aureus (HKSA). 2 Two particular tyrosine residues have been identified as possible phosphoacceptors. A Tyr-616, Tyr-761 double mutant not only abolishes NF-κB-dependent reporter activity but also prevents the recruitment of the p85 subunit of phosphatidylinositol-3 kinase (PI3K). PI3K acts as an effector of Rac1, a small G protein involved in the transactivation of NF-κB. 3 The p85 subunit of PI3K binds to phospho-tyrosine residues via a src-homology domain. Phosphorylation of TLR2 by an as yet unidentified kinase induces the formation of an active TLR2-Rac1-PI3K complex. The adaptors Mal and MyD88 are presumably recruited to the receptor at the same time and initiate a signaling pathway leading to IκB degradation and nuclear translocation of active p50/p65 NF-κB heterodimers. Full activation is then imparted on the transcriptional machinery following the phosphorylation of p65, a process known as transactivation. This is presumably mediated by the Rac1/PI3K arm of the TLR2 pathway. Akt, a protein kinase situated downstream of PI3K, has also been implicated here as a dominant negative form of the protein was able to block NF-κB-dependent gene transcription in HSKA-stimulated cells. 2 In an analogous scenario, phosphorylation of the interleukin-1 (IL-1) receptor on Tyr-479 was also shown to be required for PI3K recruitment and subsequent NF-κB activation following exposure to IL-1. 4 TLR-1, TLR-2 and TLR-6 all contain putative PI3K binding sites as does MyD88; however, this domain is not present in other TLRs. Recently, PI3K was implicated in the TLR4 signaling pathway, again acting as a mediator of NF-κB transactivation. 5 PI3K does not bind directly to TLR4 but rather interacts with TLR4 through MyD88 which was also shown to undergo transient phosphorylation following LPS treatment. The timecourse of phosphorylation paralleled the interaction of MyD88 with the p85 subunit of PI3K. In this context, MyD88 has a dual capacity: on the one hand it can activate components of the TLR4 pathway leading to IκB degradation and nuclear translocation of NF-κB; and, on the other hand, it can induce the phosphorylation of p65 via its interaction with PI3K. TLR3 contains 5 tyrosine residues; Tyr-759 is the most membrane proximal while Tyr-858 is most distal. A detailed study of the phosphorylation status of TLR3 was recently carried out by Sarkar and colleagues. 6 A construct in which tyrosines 759 and 858 were mutated simultaneously to phenylalanine was completely impaired in its ability to activate dsRNA-induced gene induction. TLR3 differs from other TLRs in that it does not recruit the universal adaptor MyD88 (or Mal/TIRAP) but instead recruits TRIF, 7 a partnership that leads to the induction of anti-viral genes via the kinases NAP1, IKKi/TBK1 and the transcription factor IRF3. 8 (TLR3 can also activate NF-κB through a RIP1/IKKi/TBK1 pathway. 9 ) In a follow-up study, Sakar and colleagues demonstrated that TLR3 also recruits PI3K and that phosphorylated Tyr-759 acts as a docking site for this interaction. 10 Mutation of this residue to phenylalanine not only prevented TLR3/PI3K complex formation but also resulted in only a partial phosphorylation of IRF3 and a failure to induce target genes. In a simplified scenario, phosphorylated TLR3 recruits both TRIF and PI3K. TRIF, in turn, recruits the kinase complex NAP1/IKKi/TBK1 leading to partial IRF3 phosphorylation. At the same time, PI3K (presumably acting through AKT) initiates a kinase cascade that results in full IRF3 phosphorylation and transcriptional activation. This pathway mimics the one seen with TLR2 and TLR4 where PI3K mediates the transactivation of NF-κB. TLR3 does not contain a putative PI3K binding site and it is unclear, at present, if this interaction is direct. What is clear, however, is that tyrosine phosphorylation adds an additional level of control over TLR signaling pathways.
Identification and targeting of the kinases involved in TLR modification would be a powerful therapeutic tool, particularly if individual kinases modify specific TLRs. Candidate kinases implicated in TLR4 phosphorylation include src, fyn, hck and most notably Btk which may be an effector of PI3K on the p65 transactivation pathway (S. Doyle, personal communication).
Phosphorylation of adaptor proteins
As mentioned above, phosphorylated MyD88 can be detected in cell lysates following exposure to LPS. 5 It is not clear, at present, whether this modification is required for interaction of MyD88 with the p85 subunit of PI3K and/or whether other signals mediated by MyD88 are phosphorylation dependent. Recently, Naiki and co-workers demonstrated that transforming growth factor beta 1 (TGF-β1), a potent anti-inflammatory cytokine, inhibits TLR signaling by facilitating the ubiquitination and proteosomal degradation of MyD88. 11 In many instances, protein phosphorylation precedes ubiquitination, a classic example being the ubiquitination and subsequent degradation of IκBα. It will be interesting to discover if phosphorylation of MyD88 also determines its eventual fate. The specific residues involved have not yet been identified but one would predict that if phosphorylation is required for ubiquitin ligation then a mutant MyD88 protein would have a prolonged half-life.
We have reported previously that overexpression of the adaptor protein Mal in cells gives rise to the appearance of multiple bands on SDS-PAGE electrophoresis suggesting that Mal is also a phosphoprotein. 12 Phosphorylation of TRIF and TRAM has not yet been reported; however, it would not be surprising if these adaptors also undergo similar modifications.
Phosphorylation of IRAK family members
Four IRAK family members have been identified so far. IRAK-1 and IRAK-4 are active enzymes whereas IRAK-2 and IRAK-M are catalytically inactive due to the absence of key residues in their respective kinase domains. [13] [14] [15] [16] IRAK-2 retains the ability to activate NF-κB whereas IRAK-M acts as a negative regulator of TLR signaling. 17 Deletion of IRAK-4 from cells completely abrogates responsiveness to IL-1 and TLR ligands, 18 while deletion of IRAK-1 also dramatically impairs ligandinduced gene expression. 19 On activation, IRAK-1 becomes heavily phosphorylated giving rise to additional high molecular weight forms of the protein on SDS-PAGE electrophoresis. Prior to activation, IRAK-1 is associated with a receptor complex containing MyD88 and Tollip. 20 In order to transduce downstream signals, IRAK-1 must leave the receptor complex and engage with TRAF6 and a TAK1-TAB1-TAB2 kinase complex. Kollewe and co-workers have used a series of IRAK peptides and deletion mutants to order the sequence of events preceding the dissociation of IRAK-1. 21 It is thought that IRAK-1 is initially phosphorylated on Thr-209 which lies in the ProST region of the protein.
In vitro, this reaction is catalysed by IRAK-1 itself; however, phosphorylation of a peptide containing this residue was also observed with IRAK-4. Addition of a phosphate group results in a conformational change in IRAK-1 and effectively opens the kinase domain to expose an activation loop which is then phosphorylated on Thr-387 and results in a full enzymatic activity. At this point, IRAK-1 undergoes extensive hyperphosphorylation in the ProST region leading to its eventual dissociation from MyD88 and Tollip and engagement with downstream signaling proteins. Hyperphosphorylation of IRAK-1 also serves to limit the availability of the protein which undergoes phosphorylation-dependent proteolytic degradation (see below). 22 IRAK-4 also undergoes phosphorylation when overexpressed in cells; however, it is not clear at present if this is an autophosphorylation event or if indeed another kinase is involved.
It should be noted that the kinase activity of IRAK-1 is dispensable for its function, at least for IL-1 mediated signaling. Li and co-workers have shown that a kinaseinactive (K239A) mutant can still drive IL-1-mediated responses in IRAK deficient cells. 23 This group has also shown that the kinase activity of IRAK-4 is redundant for IL-1 signaling and suggests that IRAK-4 functions as an adaptor to recruit IRAK-1 to the IL-1 receptor complex. 24 These studies were carried out in human cells and differ from those seen in mouse cells were the kinase activity of IRAK-4 is required for optimal transduction of IL-1 and TLR signals. 25 The reasons for these discrepancies are unclear at present but may reflect inter-species and/or tissue and cell-type variation. A comparative study will no doubt clarify the importance of these kinases in IL-1 and TLR signaling.
UBIQUITINATION
TRAF6 functions as a ubiquitin ligase
Upon activation, IRAK-1 engages with TRAF6, a member of the TNF-receptor-associated factor (TRAF) family of proteins. 26 TRAF6 functions in both TNF-receptor and IL-1R/TLR signaling and regulates an array of physiological processes including inflammatory responses and bone metabolism. 27, 28 It has recently been demonstrated that TRAF6 undergoes ubiquitination following cell stimulation and that TRAF6 itself is a ubiquitin ligase. 29 This modification does not prime TRAF6 for degradation but rather activates the protein and subsequent downstream kinase cascades.
TRAF6 belongs to the RING (really interesting new gene) family of ubiquitin ligases which are classified by a short cysteine and histidine-rich region that co-ordinates two zinc ions. 30 Ubiquitination occurs in three distinct steps: first, an inactive ubiquitin precursor molecule is processed by a ubiquitin-activating enzyme (E1). The activated molecule is then transferred to a cysteinyl group on a ubiquitin-conjugating enzyme (E2). Finally, a ubiquitin-protein ligase (E3) promotes the transfer of ubiquitin from the E2 to a lysine residue on the substrate molecule. Repeated transfers of ubiquitin result in the formation of polyubiquitin chains that induce either proteolytic degradation or activation of the substrate depending on which lysine residue is modified. For example, Lys-48 polymers target proteins for ATPdependent proteolysis by the 26S proteosome 31 whereas Lys-63 linkages modulate protein function in the absence of degradation. 32 TRAF6 functions in conjunction with the Ubc13-Uev1A E2 complex to catalyse the synthesis of a unique Lys-63 linked polyubiquitin chain. 29 One of the targets of ubiquitination is TRAF6 itself, a process that requires its oligomerization. Ea and co-workers have recently shown that TIFA (TRAF-interacting protein with a forkhead-associated domain), a TRAF6 interacting protein, induces TRAF6 oligomerization and subsequent polyubiquitination. 33 Mutation of the TRAF6 binding site in TIFA abolishes the ability of TIFA to activate IKK in vitro. In addition, the TRAF6 binding mutant failed to enhance the ligase activity of endogenous TRAF6 in reconstitution assays. Oligomers of the paracaspase, MALT1, which is involved in the activation of NF-κB following T-cell receptor stimulation, have also been shown to induce TRAF6 oligomerization again resulting in the activation of TRAF6 ubiquitin ligase activity. 34 TRAF6 is composed of a RING domain, a C-terminal TRAF domain and an N-terminal domain that is predicted to form a coiled-coil structure. 35 Yang and co-workers have shown that this region (amino acids 292-358) mediates the interaction between TRAF6 and the Ubc13-Uev1A E2 ligase complex. Deletion of this region abolishes this interaction and the subsequent auto-ubiquitination of TRAF6. 36 Peptides targeting this region may, therefore, have the potential to inhibit overactive immune and inflammatory responses.
Once ubiquitinated, TRAF6 activates IKK through a TAK1-TAB1-TAB2 kinase complex. 37 Ea and co-workers have also demonstrated that TAB2 binds to Lys-63 linked polyubiquitin chains through a conserved novel zinc finger (NZF) domain which is essential for TAK1 activation. 38 Once activated, TAK1 phosphorylates the activation loop of IKKβ, thereby activating the IKK complex. TAK1 also phosphorylates MKK6 and MKK7, which in turn activate the p38 and JNK kinase pathways, respectively. 37
A20 terminates Toll-like receptor responses
As TRAF6 is not degraded following ubiquitination, it is not surprising that a mechanism exists to remove ubiquitin moieties and return TRAF6 to its pre-activation state. This mode of regulation is mediated by a class of enzymes known as de-ubiquitinating enzymes (DUBs). 39 These molecules also serve as proof-reading enzymes to recycle proteins that have been incorrectly targeted by the ubiquitination machinery. Jensen and co-workers first demonstrated that TRAF6 is recycled via de-ubiquitination following treatment of liver cells with IL-1. 40 TRAF6 re-appeared in cells lysates in a non-modified state after 30-min stimulation. Actinomycin D or cycloheximide pretreatment failed to inhibit the regeneration of non-modified TRAF6. Recently, Boone and colleagues demonstrated that the de-ubiquitinating enzyme A20 terminates Toll-like receptor responses by removing ubiquitin moieties from TRAF6. 41 In these studies, mice deficient for A20 were susceptible to endotoxin-induced shock while reconstitution with wild-type hematopoietic stem cells afforded protection against aberrant LPS responses. When recombinant A20 was incubated with ubiquitinated TRAF6, a significant reduction in the ubiquitinated species was observed. A critical cysteine (Cys-103) residue found in the OTU (ovarian tumour) domain of A20 was identified as being essential for proteolytic activity and mutation to alanine prevented de-ubiquitination. A20-deficient macrophages also showed enhanced NF-κB activity in response to TLR2, TLR4 and TLR9 ligands suggesting that A20 is a universal regulator of TLR signaling.
Indeed, A20 expression is induced by a variety of stimuli including LPS, TNF-α and poly-IC. 42 It has recently been demonstrated that A20 is also induced upon viral infection suggesting a role for A20 in the response to viral pathogens. 43 Saitoh and co-workers have now shown that A20 interacts with the IRF3 kinases, TBK1 and IKKi, to inhibit TLR3-mediated IRF-3 activation. 44 Phosphorylation of IRF-3 by TBK1 was inhibited in cells overexpressing exogenous A20 while reduction of A20 levels using small interfering RNAs resulted in enhanced IRF-3 activation. A20 is unusual in that it contains a de-ubiquitinating domain as well as a ubiquitin ligase domain. Wertz and colleagues have demonstrated that A20 uses both domains independently to negatively regulate NF-κB signaling following TNF-receptor stimulation. 45 The N-terminal domain of A20 initially removes Lys-63-linked ubiquitin chains from the essential adaptor receptor interacting protein (RIP). The carboxy-terminal domain of A20 then functions as a ubiquitin ligase to catalyse the addition of Lys-48-linked polyubiquitin chains to RIP, thereby targeting it for proteosomal degradation. It has not yet been established if the E3 ligase activity of A20 is required for TLR signaling. As mentioned above, RIP1 has been shown to modulate TLR3 responses; 9 it is, therefore, possible that A20 also has dual ubiquitin-editing functions in the TLR3 pathway.
TRIAD3 catalyses the ubiquitination of Toll-like receptors
It will be interesting to discover if other A20-like molecules with dual activities target additional components of the TLR family in a similar manner. As mentioned above, MyD88 undergoes ubiquitin-mediated proteolysis in the presence of TGF-β1 while IRAK-1 undergoes ubiquitination and degradation following IL-1 and TLR stimulation. 22 This is not the first point in the pathway at which ubiquitination occurs. Triad3A, a novel E3 ubiquitinligase, has been shown to enhance the ubiquitination and degradation of some TLRs. 46 It was initially identified through a yeast two-hybrid screen using the cytoplasmic domain of human TLR9 as bait. The protein is so called because it contains a TRIAD domain which is present in some E3 ubiquitin ligases. 47, 48 This prompted investigators to assess whether Triad3A functions in this capacity. Overexpression of exogenous Triad3A with a tagged form of ubiquitin resulted in auto-ubiquitination of the protein. This was enhanced in the presence the proteosome inhibitor MG132, suggesting a proteolytic targeting event rather than activation. Triad3A was also shown to promote the ubiquitination and degradation of TLR9 but not TLR2. TLR4 was also degraded in the presence of Triad3A as were TLRs 3 and 5, albeit to a lesser extent. Depletion of Triad3A from cells using small interfering RNAs enhanced responses to LPS, flagellin and CpG DNA and led to increased expression of TLR4 and TLR9. The inability of Triad3A to ubiquitinate TLR2 can be explained by the lack of interaction between the two proteins when compared with the other TLRs. Triad3A is probably recruited to TLR4 and TLR9 post ligand binding as pretreatment of cells with an agent blocking TLR9 activation prevented degradation. Future crystallographic studies will identify the structural determinants required for these interactions.
Activation of transcription factors following TLR stimulation
Several transcription factors are known to be regulated by ubiquitination; in fact, c-Jun was one of the earliest to be identified. 49 The E3 ligase that catalyses the ubiquitination and subsequent degradation of c-Jun belongs to the HECT (homology to the E6-associated C-terminus) family of E3 ligase and is referred to as Itch, 50 so called because of the constant itching observed in Itch knockout mice. 51 The MAPK kinase kinase, MEKK1, also exhibits E3 ligase activity and mediates the ubiquitination and degradation of Erk1/2, therefore acting as both a positive and negative regulator of the Erk pathway. 52 NF-κB is the primary transcription factor activated following TLR stimulation and is responsible for the expression of a wide variety of inflammatory mediators. As mentioned earlier, IκBα forms an inactive complex with NF-κB in the cytosol of resting cells. Upon stimulation, an activated IKK complex phosphorylates IκBα on ser-32 and ser-36 which creates a docking site for an E2 ubiquitin ligase complex containing β-TrCP, Skp1, Cullin1 and Roc1. 29 Roc 1 then recruits ubiquitin-loaded Ubc E2 to transfer ubiquitin to the IκB protein, thus marking it for degradation by the 26S proteosome. Degradation occurs rapidly and correlates with the initiation of gene induction by active NF-κB dimers. Recently, Abbott and co-workers demonstrated that NEMO, the regulatory subunit of the IKK complex, undergoes NOD2 and RIP2-dependent ubiquitination on lysine-285 which results also in the activation of NF-κB. 53 NEMO is not degraded post-ubiquitination, this again being another example of ubiquitin-mediated activation. Polymorphisms in the gene encoding NOD2 are associated with Crohn's disease and a decreased ability to ubiquitinate NEMO. This would suggest that this mode of regulation may be a factor underlying the pathogenesis of Crohn's disease.
As mentioned above, IRF-3 is activated following TLR3 stimulation by a kinase complex containing NAP1/TBK1/IKKi. 8 A series of serine phosphorylations trigger the dimerization and nuclear translocation of IRF-3 resulting in the induction of interferon-β (IFN-β). Secreted IFN-β then induces the expression of several anti-viral genes via the Jak-STAT pathway. In plasmacytoid cells, IRF-7 induces the production of IFN-α following exposure to ligands for TLR7, TLR8 and TLR9. Kawai and co-workers have shown that IRF-7 interacts with both MyD88 and TRAF6. 54 Silencing of the ubiquitinconjugating enzyme, UBC13, reduces the activation of IFN-α promoters indicating that the ubiquitin ligase activity of TRAF6 is required for the activation of IRF-7. Phosphorylation of IRF-7 has been demonstrated; however, the kinase responsible has not yet been identified. It has been suggested that IRF-7 may be recruited to a TRAF6/TRIF complex where it is phosphorylated by the TBK1/IKKi kinases; however, further experiments are required to clarify this point. Activation  IRF-3  Phosphorylation  Activation  IRF-7 Ubiquitination Activation *TF, transcription factor. IRF-5 is the latest member of the IRF family found to be activated by TLR ligands. 55 IFN-α production is normal in IRF-5 deficient mice. However, induction of pro-inflammatory cytokines in response to various TLR ligands is severely impaired. These mice are also resistant to lethal shock induced by LPS or CpG DNA. Takaoka and colleagues demonstrated that IRF-5, like IRF-7, complexes with MyD88 and TRAF6. Hence, IRF-5 displays characteristics comparable to IRF-7 and may, therefore, be modified by TRAF6 in a similar manner.
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PERSPECTIVES
The co-ordinated positive and negative regulation of TLR signaling ensures the appropriate modulation of inflammatory responses. In chronic inflammatory disease, this level of control is lost. A number of negative regulators of TLR signalling have recently been described. For example, ST2, IRAK-M and MyD88s all function to sequester components of the TLR pathway. 17, 56, 57 The post-translational modification of TLR signaling molecules adds an additional level of control over these pathways. Table 1 and Figure 1 summarize these modifications. Identification and targeting of the enzymes involved will be a powerful therapeutic tool given the level of specificity involved. 
